Search

Veracyte Inc

Open

SectorGezondheidszorg

41.21 -3.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

40.98

Max

43.6

Belangrijke statistieken

By Trading Economics

Inkomsten

-3.2M

25M

Verkoop

11M

150M

K/W

Sectorgemiddelde

33.774

57.002

EPS

0.37

Winstmarge

16.957

Werknemers

755

EBITDA

-11M

24M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+35.56% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-718M

3.7B

Vorige openingsprijs

44.25

Vorige sluitingsprijs

41.21

Nieuwssentiment

By Acuity

50%

50%

171 / 340 Rangschikking in Healthcare

Veracyte Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 aug 2026, 19:51 UTC

Veracyte Inc shares are lower today, breaking a trend of higher closes. No specific news was identified for this decline amid notable market volume.

12 aug 2026, 20:01 UTC

Veracyte Inc shares are lower today, following a broader market decline. The stock remains significantly below its 20-day moving average.

11 aug 2026, 19:26 UTC

News

Veracyte Inc reported second-quarter revenue of $150.32 million and raised its 2026 outlook to $590 million to $596 million, boosting shares higher.

10 aug 2026, 19:36 UTC

News

Veracyte Inc shares declined Monday, trading lower since Friday's close amid broader market volatility and rising oil prices affecting inflation expectations.

7 aug 2026, 19:26 UTC

Correlated Moves

Veracyte Inc shares are higher, supported by a rise in the ARK Genomic Revolution ETF and broader small-cap strength from the Russell 2000 Index.

6 aug 2026, 19:26 UTC

Veracyte Inc shares are higher today, despite earlier losses. No specific news was identified to explain the price movement during the session.

5 aug 2026, 19:32 UTC

Veracyte Inc's shares are lower, reflecting broader market sentiment amid recent crude oil price declines. Trading volume is unusually high today.

4 aug 2026, 19:36 UTC

News
Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

3 aug 2026, 20:06 UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

1 aug 2026, 00:01 UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

31 jul 2026, 20:02 UTC

News
Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

30 jul 2026, 23:21 UTC

News
Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

29 jul 2026, 19:47 UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

28 jul 2026, 15:22 UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

27 jul 2026, 20:14 UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

24 jul 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22 jul 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 jul 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20 jul 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Peer Vergelijking

Prijswijziging

Veracyte Inc Prognose

Koersdoel

By TipRanks

35.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 57.75 USD  35.56%

Hoogste 70 USD

Laagste 44 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Veracyte Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

8

Buy

1

Hold

1

Sell

Sentiment

By Acuity

171 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
help-icon Live chat